2026-09-16T20:10:09.000Z · 13 days ago AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
Sep 16, 2026, 4:05 PM EDT · 13 days ago AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Sep 2, 2026, 4:05 PM EDT · 27 days ago AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Aug 13, 2026, 12:05 AM EDT · 6 weeks ago AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Aug 11, 2026, 4:01 PM EDT · 7 weeks ago AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-08-10T19:55:32.000Z · 7 weeks ago AbCellera price target raised to $25 from $13 at JonesResearch
Aug 10, 2026, 7:23 AM EDT · 7 weeks ago This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.
Aug 10, 2026, 7:13 AM EDT · 7 weeks ago AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
2026-08-10T11:11:27.000Z · 7 weeks ago AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints
Aug 10, 2026, 7:00 AM EDT · 7 weeks ago AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
Aug 7, 2026, 4:30 PM EDT · 7 weeks ago AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
2026-08-06T12:12:02.000Z · 7 weeks ago AbCellera price target raised to $12 from $11 at Cantor Fitzgerald
2026-07-29T11:27:06.000Z · 2 months ago AbCellera announces collaboration with Vertex Pharmaceuticals VRTX
Jul 29, 2026, 7:00 AM EDT · 2 months ago AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
Jul 7, 2026, 4:05 PM EDT · 2 months ago AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Jun 17, 2026, 7:43 AM EDT · 3 months ago Jazz Pharma, AbCellera ink antibody deal worth up to $876 million JAZZ
Jun 17, 2026, 7:00 AM EDT · 3 months ago Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Jun 5, 2026, 9:00 AM EDT · 3 months ago AbCellera Appoints Dr. Victor Sandor to its Board of Directors
May 11, 2026, 4:05 PM EDT · 4 months ago AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
May 7, 2026, 4:05 PM EDT · 4 months ago AbCellera to Present at Upcoming Investor Conferences in May and June 2026
Apr 20, 2026, 9:00 AM EDT · 5 months ago AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Apr 1, 2026, 4:05 PM EDT · 6 months ago AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
Feb 11, 2026, 4:05 PM EST · 7 months ago AbCellera to Present at Upcoming Investor Conferences in March and April 2026
Jan 22, 2026, 4:05 PM EST · 8 months ago AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Jan 12, 2026, 9:00 AM EST · 8 months ago AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
Dec 18, 2025, 9:00 AM EST · 9 months ago AbCellera and Bruker Reach Global Settlement of Patent Litigation
Dec 8, 2025, 4:05 PM EST · 9 months ago AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Nov 10, 2025, 9:00 AM EST · 10 months ago AbCellera Appoints Dr. Stephen Quake to its Board of Directors
Oct 7, 2025, 4:05 PM EDT · 11 months ago AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
Sep 29, 2025, 4:05 PM EDT · 1 year ago AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
Sep 10, 2025, 9:07 AM EDT · 1 year ago AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
Aug 27, 2025, 9:00 AM EDT · 1 year ago AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
Aug 12, 2025, 4:05 PM EDT · 1 year ago AbCellera to Participate at Upcoming Investor Conferences in September
Aug 7, 2025, 4:05 PM EDT · 1 year ago AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
Jul 7, 2025, 4:05 PM EDT · 1 year ago AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
May 30, 2025, 1:00 PM EDT · 1 year ago AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
May 14, 2025, 5:00 PM EDT · 1 year ago AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
May 12, 2025, 3:30 PM EDT · 1 year ago AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
May 9, 2025, 7:30 PM EDT · 1 year ago AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
Apr 29, 2025, 3:00 PM EDT · 1 year ago AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
Apr 8, 2025, 4:05 PM EDT · 1 year ago AbCellera to Participate at Upcoming Investor Conferences in May and June
Apr 3, 2025, 4:05 PM EDT · 1 year ago AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
Mar 25, 2025, 4:30 PM EDT · 1 year ago AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
Feb 11, 2025, 4:05 PM EST · 1 year ago AbCellera to Participate at Upcoming Investor Conferences in March
Jan 21, 2025, 4:05 PM EST · 1 year ago AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
Jan 13, 2025, 9:00 AM EST · 1 year ago AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
Nov 21, 2024, 4:05 PM EST · 1 year ago AbCellera to Present at Upcoming Investor Conferences in December and January
Nov 7, 2024, 10:05 AM EST · 1 year ago AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024